Search Results - "Biasi, O.M."

141P Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC) by Dugo, M., Gyorffy, B., Bisagni, G., Colleoni, M.A., Mansutti, M., Zamagni, C., Del Mastro, L., Zambelli, S., Frassoldati, A., Licata, L., Galbardi, B., Biasi, O.M., Viganò, L., Locatelli, A., Viale, G., Valagussa, P., Viale, G., Callari, M., Gianni, L., Bianchini, G.

Get full text

Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study by Luen, S.J., Asher, R., Lee, C.K., Savas, P., Kammler, R., Dell’Orto, P., Biasi, O.M., Demanse, D., Hackl, W., Thuerlimann, B., Viale, G., Di Leo, A., Colleoni, M., Regan, M.M., Loi, S.

“…In postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, the risk for distant recurrence…”
Get full text